世界中医药

目的：观察Rho激酶抑制剂、芪苈强心胶囊分别及联合短期应用对慢性心力衰竭患者细胞因子(肿瘤坏死因子-α、白细胞介素-6)水平的作用，并探讨其机制。方法：120例慢性心力衰竭患者(NYHA分级Ⅱ～Ⅲ级)在接受常规心力衰竭治疗的基础上，随机分成4组，分别是空白对照组(30例)(A组)，单用Rho激酶抑制剂治疗组(30例)（B组），单用芪苈强心胶囊治疗组（30例）（C组）和Rho激酶抑制剂与芪苈强心胶囊联合治疗组（30例）（D组）共治疗4周。治疗前后测定肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、BNP，评估心功能。结果：治疗后3个治疗组B、C、D组分别与对照组A组相比TNF-α、IL-6、BNP水平均明显降低(P<0.05)，治疗组间（B、C、D组间）比较B组与C组间无统计学意义（P>0.1），D组较B组、C组均有统计学意义(P<0.05)。结论：Rho激酶抑制剂联合芪苈强心胶囊能显著降低慢性心力衰竭患者血清细胞因子TNF-α、IL-6水平，改善心功能，有利于慢性心力衰竭的治疗。

English Summary:

To observe the short term effects of Rho-kinase inhibitor and Qiliqiangxin capsules on serum tumor necrosis factor-alpha(TNF-α)and interleukin-6(IL-6)levels in patients with chronic heart failure，and explore the mechanism.Methods：120 chronic heart failure patients received conventional treatment for 4 weeks were divided into blank control group (30 cases)（Group A），Rho-kinase inhibitor-treated group (30 cases)（Group B），Qiliqiangxin capsules-treated group(30 cases)（Group C），and the other 30 cases in the treatment with Rho-kinase inhibitor combined with Qiliqiangxin capsules（GroupD）.TNF-α，IL-6 and cardiac function evaluated by BNP were measured before and after treatment.The difference between the 4 groups was analyzed.Results：The baseline of TNF-α，IL-6 and cardiac function was not significantly different in 4 groups (P>0.05).TNF-α and IL-6 levels in Rho-kinase inhibitor combined with Qiliqiangxin capsules（GroupD）were significantly lower than other groups after 4 weeks’ treatment (P<0.05).Conclusion：Rho-kinase inhibitor combined with Qiliqiangxin capsules can improve cardiac function，reduces levels of serum cytokines associated with chronic heart failure.

查看全文查看/发表评论下载PDF阅读器